What is CorMedix Inc (CRMD) stock price today?

CorMedix Inc (CRMD) currently trades at $7.48 per share. The stock has a market capitalization of $586.55M and a P/E ratio of 3.64x.

Is CRMD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, CorMedix Inc has a Smart Value Score of 70/100 (Grade B), resulting in a "Buy" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is the CRMD stock price target for 2026?

WallStSmart's 12-month price target for CorMedix Inc is $5.29.

What is CorMedix Inc's revenue and earnings?

CorMedix Inc has trailing twelve-month (TTM) revenue of $311.71M with profit margins of 52.30%. Earnings per share (EPS) is $2.04.

CRMD

CorMedix Inc

NASDAQ: CRMD · HEALTHCARE · BIOTECHNOLOGY

$7.48

-1.19% today

Updated 2026-04-29

Market cap

$586.55M

P/E ratio

3.64

P/S ratio

1.88x

EPS (TTM)

$2.04

Dividend yield

—

52W range

$6 – $17

Volume

1.3M

Market cap

$586.55M

P/E ratio

3.64

P/S ratio

1.88x

EPS (TTM)

$2.04

Dividend yield

—

52W range

$6 – $17

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: B

Buy

Investment rating

5.7

Growth

C+

5.0

Quality

C+

10.0

Profitability

A+

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$14.57

+94.79%

12-Month target

$5.29

-29.28%

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Profit margin 52.30% — above average

+ ROE 66.60% — strong efficiency

+ Free cash flow $94.42M — positive

+ Revenue growth 312.10% QoQ

Risks

No major risks identified

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$65408.00	$0.00	$43.47M	$311.71M	$311.71M
Net income	$-29.70M	$-46.34M	$-17.93M	$163.06M	$14.02M
EPS	—	—	—	—	$2.04
Free cash flow	$-24.58M	$-38.74M	$-50.73M	$172.79M	$94.42M
Profit margin	-45,409.90%	—	-41.24%	52.31%	52.30%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-04	ZELNICK, KAUFMAN BETH	Buy	36,006	—
2026-02-04	TODISCO, JOSEPH	Buy	77,156	—
2026-02-04	HURLBURT, ELIZABETH	Buy	36,006	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CRMD	$586.55M	70	5.7	10.0	6.7	5.0	—	Strong Buy
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

CorMedix Inc trades at $7.48. representing a P/E of 3.64x trailing earnings. Our Smart Value Score of 70/100 indicates the stock is good. TTM revenue stands at $311.71M. with profit margins at 52.30%.

Frequently asked questions

What is CorMedix Inc's stock price?

CorMedix Inc (CRMD) trades at $7.48.

Is CorMedix Inc overvalued?

Smart Value Score 70/100 (Grade B, Buy).

What is the price target of CorMedix Inc (CRMD)?

The analyst target price is $14.57, representing +94.8% upside from the current price of $7.48.

What is the future stock price of CRMD by 2030?

Our revenue-driven model estimates CorMedix Inc could reach $13.86 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.

What is CorMedix Inc's revenue?

TTM revenue is $311.71M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.88x

ROE66.60%

Beta1.41

50D MA$6.96

200D MA$9.93

Shares out0.08B

Float0.07B

Short ratio—

Avg volume1.3M

Performance

1 week+0.81%

1 month+6.55%

3 months-3.61%

YTD-35.68%

1 year—

3 years—

5 years—

Compare

CRMD vs LLY →CRMD vs JNJ →CRMD vs ABBV →Stock screener →